Plexxikon’s unique discovery platform allows for the creation of novel, competitively differentiated drugs that have improved pharmacologic properties over many of today's available therapies.
The company has demonstrated the ability to move multiple programs from discovery to IND in just two years, significantly improving typical pharmaceutical development timelines at reduced costs. Additionally, the development team has executed successfully early clinical trials, including through clinical proof-of-concept.
Plexxikon conducts research and early development studies with academic and clinical researchers worldwide. The company is particularly interested in working with leading researchers and clinical specialists to study its novel drugs in unique preclinical models and in clinical studies enriched with biomarker and diagnostic tools.